The U.S. Food and Drug Administration (FDA) has granted traditional approval to Novartis for Fabhalta (iptacopan), a groundbreaking oral Factor…
Read More
Novartis and Antares Therapeutics Forge Landmark Oncology Collaboration to Tackle Undruggable Cancer Targets
In a significant move poised to accelerate the development of novel cancer therapies, Novartis has entered into a strategic collaboration…
Read More
Novartis Breaks Ground on New Radioligand Therapy Manufacturing Facility in Denton, Texas, Bolstering US Healthcare Infrastructure
Novartis has commenced construction on a significant new radioligand therapy (RLT) manufacturing facility in Denton, Texas, a pivotal development in…
Read More
Novartis Navigates Generics Storm in Q1, Eyes Robust Future Fueled by Strategic Acquisitions and Pipeline Advancements
Novartis reported a challenging first quarter for 2026, with profits experiencing a significant downturn primarily due to the intensified impact…
Read More
Novartis Secures Dual Regulatory Milestones: European Approval for Rhapsido and WHO Prequalification for Coartem Baby
Novartis has achieved significant regulatory successes on two fronts, with its oral therapy Rhapsido (remibrutinib) receiving marketing authorisation from the…
Read More
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings – Pharmaceutical Technology
The European Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions on three promising new drug candidates,…
Read More
Novartis to Acquire Excellergy for Up to $2 Billion to Bolster Next-Generation Anti-IgE Allergy Pipeline
Novartis has entered into a definitive agreement to acquire Excellergy, a privately held biotechnology company specializing in the development of…
Read More
Novartis Acquires Promising Breast Cancer Drug SNV4818 from Synnovation Therapeutics for Up to $3 Billion
Novartis has announced a significant strategic move to bolster its oncology pipeline with the acquisition of SNV4818, an investigational oral…
Read More
